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Thank you for the great honor you have bestowed
on me as your president. No one arrives here by acci-
dent, and it is with great fondness and gratitude that
I pay homage to my mentors. I have been particular-
ly blessed in my journey to cross paths with 3 very
special men: Charles Rob, James DeWeese, and Frank
Veith. Dr Rob bequeathed to me a surgical practice
and whatever artistry I might have in the operating
room. Dr DeWeese taught me how to think critically,
write, and present data. He is responsible for any
intellectual achievements I have made, the academic
position I am honored to hold, and my view of vas-
cular surgery as a unique and very special entity.1 My
vision of what Vascular Surgery must become is large-
ly attributable to Dr Veith.2
Presidential addresses challenge a few privileged
individuals to step forward and define themselves.
These opportunities sometimes demand a commit-
ment to an irreversible course of action that shapes
our personal and professional identities for years to
come.3 I believe that my vascular surgical pedigree
gives me license to do just that. Lest my references
to business strategies give the impression that I am a
closet economist and not a doctor, let me assure you
that I am first and last a clinical surgeon and teacher.
I am dedicated, like most of you, to providing
patients with state-of-the-art care and trainees with
the skills to do the same.
For many religious people, the year 2000 has
been a lodestone for apocalyptic fear and hope. You
may think that these millennialists who believe that
2000 heralds history’s last act are semi-sane, but be
careful not to dismiss the irrational as irrelevant. For
we vascular surgeons, self-proclaimed masters of our
universe, face a potential apocalypse.
Whether the end or the beginning comes with
the millennium depends on how we, as a specialty
and as individuals, respond to the challenges at hand.
My biggest fear is not that we will fail, but that we are
too apathetic to try or don’t know how to succeed.
It’s the summer of 2005. We were lulled asleep by
the encouraging demographic predictions of the mid
’90s: between 2010 and 2030, the population older
than 65 will grow from 39.4 million to 69.3 million,
32% of the voters will be older than 65, and 49% will
be older than 59 (data from Samuel H. Preston, direc-
tor of the Population Studies Center, University of
Pennsylvania). This group will have enormous power
to divert resources to itself. Medicare will be pre-
served. Best estimates indicate that more than 1 mil-
lion vascular procedures will be performed in the
United States in the year 2020.4 So what if the
American Board of Surgery (ABS) and the Residency
Review Committee (RRC) for Surgery have limited
the number of trained vascular surgeons so that more
general surgical residents could get senior level experi-
ence with vascular cases? Does it matter that we need
28 more fellowship positions starting now to meet the
conservative needs of the population through the next
20 years? All the more work for those with training.
Let those with general surgical training do the simple
cases. So what if the Food and Drug Administration
(FDA) has approved several percutaneously inserted
stent grafts and rapid-acting thrombolytic agents and
devices for clinical use? So what if only several dozen
surgical groups are able to use these emerging tech-
nologies fully? The rest of us can do them in an oper-
ating room. So what if our physicians and our industry
dedicate investment resources outside this country?
Our patients will have access to the newer technologies
after they pass the rigors of the FDA.
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If I sound like a harbinger of doom, a modern
day “Chicken Little,” please indulge me and consid-
er whether we, as individuals and as a specialty, are
ready and able to make the critical decisions neces-
sary for survival in a world where everyone sudden-
ly wants a piece of our pie? Will our progeny be
more than specialists in varicose veins, arteriovenous
access, and distal bypass?
History is replete with examples like ours: a story
of complacency disrupted by the forces generated by
discontinuous innovations. Economists describe
these events as paradigm shifts. In the beginning, a
breakthrough technology enabling unprecedented
benefits is introduced and immediately proposed as
the replacement of a whole class of infrastructure,
winning early converts and enthusiastic predictions
for a new order. Sound familiar? Let’s take the exam-
ple of communications. For the better part of a cen-
tury, we were content with letters, telegrams, and
telephones. In the past 30 years, we have adopted
answering machines, fax machines, voice mail, e-
mail, and Internet addresses. Where were you dur-
ing this change? Did you rapidly embrace the newer
technology or ignore it?
Don’t be surprised if your adoption of e-mail par-
allels your reaction to the newer technologies in vas-
cular surgery. We are conservative; we resist change,
preferring to stay with the status quo. Although
much may be written about a new paradigm, little of
significance happens, and sometimes an innovation is
never embraced. We saw that with laser angioplasty.
We first behave as a herd; we mill and mill around. In
other cases, there comes a flash point of change,
when an entire marketplace shifts its allegiance from
the old to the new. When this happens, it is unac-
ceptable not to participate. The risk of switching too
early exceeds the risk of switching too late. All of a
sudden, the risks shift; we stampede. We’re inside the
tornado.5 We’ve crossed the chasm between the early
and the mainstream markets and are entering the
period of mass-market adoption, when the general
marketplace switches to the new paradigm. Vascular
surgery has crossed the chasm. Many abdominal aor-
tic aneurysms can be repaired with stent grafts insert-
ed through the femoral artery, with early results that
already are as good or better than those achieved by
conventional methods. Those of us who have had the
opportunity to treat aneurysms with stent grafts rec-
ognized after our first case that there would be no
going back.
The design and manufacturing of high-tech
devices, once a cottage industry, has become this
decade’s equivalent to Dustin Hoffman’s “plastics”
in The Graduate. By most Wall Street estimates,
these industries are growing 20% annually. New
technologies continue to fuel this growth. For
instance, a small Minnesota-based company, Possis
Inc, makes devices for cardiology and vascular mar-
kets. Its current revenues are roughly $5 million per
year, and it lost $11 million last year. One of its 3
devices currently in testing is the AngioJet System
that removes clots from coronary arteries, peripher-
al arteries, cerebral arteries, and vascular grafts. Wall
Street estimates the market for this product alone is
$2 billion per year, and the company’s stock price
has risen 45% in the last 3 months. Corporate expec-
tation of profits of this magnitude and the relative
ease of raising venture capital in this bull market will
fuel the development of new, minimally invasive
devices for a long time to come, whether they prove
superior to conventional procedures. The challenge
to these entrepreneurial technocrats is by replacing
the old, you become the old. You cannot control the
energy of this tornado. 
Accept some responsibility if you lack catheter-
guidewire skills, because many of you have squan-
dered the opportunity to get involved with available,
innovative technologies. Do you have any personal
expertise with catheter-directed clot lysis, or do you
refer these cases to a competing interventional radi-
ologist? Are you using fluoroscopy to assist you in
the operating room? If not, referring physicians will
rapidly realize that you are an unnecessary link in the
referral chain.
Social researchers in the 1950s developed a model
of how communities respond to discontinuous inno-
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Fig 1. Schematic representation of the technology life
cycle. Very little market penetration occurs during the
early market. Crossing the chasm is required before the
mainstream market accepts an innovation. (Adapted from
Moore GA: Inside the tornado: Marketing strategies from
Silicon Valley’s cutting edge. New York: Harper Business;
1995. p. 19.)
vations. When a marketplace is faced with the oppor-
tunity to switch to a new paradigm, members segre-
gate according to their level of risk aversion.
Speculators speculate; the risk-adverse hedge.
Innovators demand to be the first to try, whereas lag-
gards retreat. These relationships can be represented
as a bell curve (Fig 1). The early market consists of the
technology enthusiasts and the visionaries. The own-
ers of the patents pertaining to aortic stent grafts,
such as Drs Balko, Lazarus, Kornberg, and Teheri, are
names that are unfamiliar to most of you. The early
adopters or visionaries are the true revolutionaries.
They are the first to exploit the new capability to
achieve a competitive advantage in the marketplace.
Their names are associated with the paradigm shift,
and their willingness to publicize the innovation gives
it a boost in the marketplace. Drs Parodi, Fogarty,
Miahle, May, and Veith, along with a number of other
investigators participating in the phase II trials, are
some of the most significant visionaries in this adap-
tive process. In this life cycle, however, the early mar-
ket means numbers of papers at vascular meetings, but
little penetration into the marketplace.
The people that determine the success of a dis-
continuous innovation are not the technicians or the
visionaries; success depends on you. The innovation
must cross the chasm, and it needs the energy from
the tornado to do this. Success depends on accep-
tance by the early majority, or the pragmatists, and
the late majority, or the conservatives. Visionaries
think pragmatists are pedestrian; pragmatists think
visionaries are dangerous.6
Pragmatists are those who do not love technolo-
gy, but are smart enough to employ those who do.
They believe in evolution, not revolution. They
adopt innovation only after a proven track record. It
is the job of the visionaries to provide scientific evi-
dence that the newer technologies are safe and effec-
tive. The conservatives undertake innovation only
under duress; they are very skeptical and very
demanding. The key to winning their support is sim-
plifying the innovation so that it just works. The lag-
gards delight in challenging innovation, continually
pointing out the conundrum physician-scientists
face as they try to provide the best and safest care
and yet validate the integrity of the data.
Moving the newer technologies into the main-
stream market will be unlike anything we’ve ever
faced, because earlier adaptations did not introduce
discontinuity into our infrastructure. Changing from
reversed to in situ saphenous vein grafts, using the
retroperitoneal approach to the abdominal aorta,
learning how to repair a thoracoabdominal aneurysm,
and doing an eversion carotid endarterectomy are
natural extensions of our skills and easily incorporated
in our training programs. Furthermore, these tech-
nologies will replace procedures that in many situa-
tions are more durable. Consider, for instance, the
shift away from aorto-femoral bypass grafts to percu-
taneous catheter-based procedures. Angioplasty and
stenting of the iliac arteries has achieved a significant
market position despite inferior results and increased
costs if one considers the lifetime of the patient and
the increased need for re-treatment. When patients
are given a choice between a groin incision or punc-
ture and a laparotomy, they will choose the former for
as long as the third-party payers allow. 
Some of us will enjoy catheter-based procedures,
others will not. Only a few of us will have the skills,
time, and interest to provide total care as individu-
als. The rest of us must offer and control access to
these same services, but have to find alternative
routes to full-service vascular surgery. We will have
to bundle our services, mixing this wide array of
products into a single service unit. Bundling is a rec-
ognized business tool for an organization that can-
not provide a full range of services in a changing
environment. When done correctly, it provides cus-
tomers with simplicity and order in a chaotic mar-
ketplace. We will have to be as good as or better than
each and every competitor, regardless of specialty. If
we lack a critical component, we will have to pur-
chase it, develop it, or make it unnecessary. Many of
you realize by now that getting the right combina-
tion into a package can be complicated.
Of course, we could secretly hope that the new
technologies fail to live up to their promise, but
reserve a right to play if they do. Boston Scientific,
Medtronic, and AVE allowed smaller entrepreneurial
enterprises to develop stent grafts and purchased the
smaller companies when it appeared that they owned
marketable technology. I remember the head of
research and development at Johnson and Johnson
telling me 5 years ago that they were going to wait
out the developmental phase of endografts and enter
the market when it penetrated the mainstream mar-
ket. Look for Johnson and Johnson to become a
player, but remember that they have more resources
than we do. If faced with the prospect of buying what
we need to compete, we will have lost all that we’ve
worked for. Instead, we must make the decision to
shape the future, taking a leadership role in how the
industry operates, setting standards, and determining
our own manpower requirements. Eastman Kodak is
clearly taking this approach by pursuing a strategy in
digital imaging as this new technology supersedes the
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one currently generating most of its earnings. We
must follow this path, even though catheter-based
procedures currently make up a very small percent-
age of our practices. Our goal should be the creation
of an organization that provides expertise in all vas-
cular problems, including knowledge of natural his-
tory, high-level interventional and surgical skills, and
the ability to monitor outcomes.
Many of you have already recognized our
predicament and have been frustrated trying to find
solutions. Either you cannot get training, or you
cannot get credentials, or you are bypassed in the
referral chain. You accept the manpower predictions
of Dr Stanley and the Committee on Workforce
Issues,7 but also silently accept the influence of the
ABS and its RRC on your lives. You come to every
1-day training session you can, but you realize that
these merely whet your interventional appetite. You
need access to the imaging facilities currently con-
trolled by your competition. Access in most situa-
tions will require a deal with catheter-based physi-
cians. If you have tried to do this, you probably real-
ize that issues such as trust, finances, egos, clinical
differences, and poor reality testing have interfered.
Equally frustrating is the impasse between vascu-
lar surgery and the ABS. I submit to you that suc-
cessful resolution of this conflict is as important to us
as a successful dialogue with the catheter-based spe-
cialties. In fact, both share a common goal: our abil-
ity to provide state-of-the-art care to our patients.
Those involved in resident training are frustrated that
the vascular trainee case load is compromised because
of minimum case requirements set for general
surgery residents by the RRC for surgery. Do you
realize that there is not a minimum number of
Whipple procedures or hepatic trisegmentectomies?
Why did the ABS try to set a minimum of 10 aortic
cases per general surgical resident? Preservation of
the status quo potentially allows inadequately trained
surgeons to think that they are vascular specialists and
compromises the experience of those who will be
designated vascular specialists. This problem is mag-
nified when we consider the impact of endovascular
procedures on our training programs.
We are fortunate at the University of Rochester to
have a sufficient operative load, so that both our single
clinical trainee and each of our 6 general surgical resi-
dents are in the 99% percentile for vascular cases. Let
me show you what is happening as we switch to the
new paradigm (Fig 2). I reviewed a 4-month experi-
ence in 1990 and found that 45 of the 50 aneurysms
operated on were conventional infrarenal aneurysms.
The other 5 aneurysms were pararenal. During a
recent 4-month period, 18 aneurysms were treated
with stent grafts, 13 aneurysms were pararenal, and 19
were infrarenal. I don’t believe that we know what a
minimum requirement should be for operations on
the aorta or any other blood vessel, but it is counter-
intuitive to think that fewer cases make better sur-
geons. I am concerned about adequate volumes of
conventional operations for our fellows and convinced
that even training programs that had surplus volumes
in the past will not be able to give general surgical res-
idents a sufficient experience without compromising
our fellows. This same analogy already pertains to the
decrease in operations for aorto-femoral occlusive dis-
ease and operations for acute limb ischemia that have
been replaced by increased use of iliac dilatation and
stenting and catheter-directed thrombolysis, respec-
tively. I submit to you that the transition to large num-
bers of endovascular cases will result in a lack of suffi-
cient numbers of conventional operations to train both
vascular and general surgical residents and will be the
final wedge that divides vascular from general surgery.
We must converse at every possible level with
those who are compromising our ability to provide
the best training and, by extension, the best care for
patients with vascular disease and change their per-
ceptions. To do this, we must adopt the principles of
game theory developed during the early days of World
War II, in which the British navy played cat and
mouse with German submarines. The theoretical 
formulation by John von Neumann and Oskar
Morgenstern, Theory of Games and Economic Strategy,
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Fig 2. Bar graph showing the types of aneurysm repair
done at the University of Rochester Medical Center dur-
ing a 4-month period in 1990 and a similar period from
1997 to 1998. The influence of endovascular repair is evi-
dent. If this trend continues, there will be insufficient
numbers of cases to train both vascular fellows and gener-
al surgical residents. Resolution of the effect of this para-
digm shift will likely drive a permanent wedge between
vascular and general surgery.
was published in 1944 and has been heralded as one
of the greatest scientific achievements of the century.
Ray Noorda, founder of Novell, calls this process
“co-opetition8”: the interplay between competition
and cooperation. It is a system for creating and cap-
turing value, a way for businesses to expand existing
markets and develop new ones. In this scenario, there
are multiple winners, because the pie gets larger.
In game theory, every enterprise can be dia-
gramed in the form of a “value net,” a visual repre-
sentation of the interrelationships among the various
players (Fig 3).9 It shows in particular how the vari-
ous players can assume different roles. A value net
for vascular surgery is shown in Fig 2. A player is a
“complementor” when your product has more value
in the marketplace with his inclusion than with yours
alone. For example, an HMO would likely value vas-
cular surgical services at a higher premium if opera-
tive cases, interventional cases, and diagnostic stud-
ies were bundled together. Likewise, a vascular sur-
geon with general surgical, vascular medicine, and
catheter-based training is a more complete and,
therefore, more valuable vascular specialist than one
with limited training. The program directors have
repeatedly endorsed the importance of general sur-
gical training as a prerequisite for a vascular fellow-
ship. A player is a “competitor” when your product
has less value when the marketplace has independent
access to his product. You can quickly see how those
players who could be complementors can be com-
petitors. The program directors also acknowledge
that in preparing some general surgical residents for
vascular fellowships, they also prepare others to go
into the communities and practice vascular surgery.
The relationships become even more compli-
cated when the customers and the suppliers enter
the picture. For example, a player is your comple-
mentor when it’s more attractive for a supplier 
to provide you with resources when he’s also sup-
plying the other player. Consider the creation 
of an operating room interventional suite, some-
thing that I believe is essential for any institution
interested in these new technologies. Hospital 
CEOs relish the thought of investing in a joint
enterprise that would create new markets when
surgery, radiology, and anesthesiology give sup-
port. Consider the same scenario when the radiol-
ogists resist placing “their” equipment in “our”
house. Complementor quickly becomes competitor.
Consider when general surgical trainees attempt to
become vascular surgeons without additional train-
ing. Complementor quickly becomes competitor.
Recognize that the same player can occupy multiple
parts of the value net and that complementors make
markets, whereas competitors divide them.
It is sometimes difficult to accept the concept that
the best way to succeed is to let others do well, includ-
ing your competitors. Even complementors are not
your partners. Remember, however, that it is not a
matter of whether others win, it is only important that
you win. This does not translate into act nice and
hope others reciprocate. That is a lose-win formula.
You do not have to rely on the goodwill of others to
succeed in our complicated marketplace. Co-opeti-
tion requires you to put yourself in the other person’s
shoes to assess how valuable you are to them, to antic-
ipate their reactions to your actions, and to under-
stand how they see the game. You must empathize
with their point of view and feel their emotions to
influence them. Recognize the fear the intervention-
alists have when we enter what they consider to be
their universe. Recognize how threatened the ABS
feels at the prospective loss of vascular surgery. In the
end, we must change their perceptions of us as com-
petitors and make them see us as complementors. We
must show them how to enlarge the pie.
A number of groups around the country have
asked me how we came to an agreement on salaries
with our interventional radiologists. This seems to
be a stumbling block in many ongoing dialogues. It
shouldn’t be. The key to understanding how the pie
gets split is all in the concept of “added value,” a
measurement of what each player brings to the
game. Your added value equals the size of the pie
when you play less the size of the pie when you
don’t play. If you demand more than you bring,
you’ve left the other players with less than they have
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Fig 3. The value net, a game theory diagram depicting
the relationships commonly encountered in any business.
The critical concept is the possibility of a single player
occupying multiple sites on the net. Complementors make
markets; competitors divide them.
without you, and your negotiations won’t go any-
where. Don’t expect more than your added value,
but don’t accept less. To accept less is not knowing
how to play in the game.
Let’s consider the discussions between vascular
surgeons and the ABS. It’s clear how that body and
its RRC have become both complementor and com-
petitor. Residencies provide us with fellows and the
community with surgeons who may also provide vas-
cular care. The training requirements for these gen-
eral surgeons dilute the experience of the vascular
trainee and limit the number of trainees we can pro-
duce. Given our increasing manpower needs, our
inability to influence so many other facets of our
lives as a specialty, and the rapidly changing tech-
nologies, I believe that it is inevitable that there will
be an American Board of Vascular Surgery.
This is not because the ABS hasn’t recently
attempted to address their years of inattention to vas-
cular surgery’s needs. It is not because a few trouble-
makers are acting out of personal avarice, as some ill-
informed colleagues have suggested in the overheat-
ed rhetoric that has accompanied this debate. As
much as the ABS might argue to the contrary, vascu-
lar surgery is fundamentally different as a conse-
quence of new technologies and new knowledge.
The argument that current general surgeons perform
a significant number of vascular procedures is mis-
leading and irrelevant. Most index vascular cases are
clearly done by vascular surgeons, whereas general
surgeons perform most angioaccess and venous
surgery. In addition, we are talking about future sur-
geons and the ability to determine numbers and cur-
ricula to meet our obligation to provide the best pos-
sible care for patients with vascular disease. We must
further recognize that endovascular procedures will
substantially reduce the numbers of conventional
operations and that there will not be enough cases to
train both general surgical trainees and vascular fel-
lows. We must have an RRC for vascular surgery that
has authority and responsibility for vascular matters
that have previously been assumed by the ABS, and
this cannot happen without our own board. In par-
ticular, an RRC for vascular surgery would ensure
that evaluation and approval of general surgery and
vascular surgery training programs would cease to be
interdependent, that censure of one program would
not obligate censure of the other, and that case dis-
tribution issues would be settled at the local level.
The Accredidation Council for Graduate Medical
Education will not spin off the responsibilities of the
RRC for surgery to a separate RRC unless there is an
entirely separate board involved.
We should empathize with the ABS position on
these issues. Its primary purpose, adopted at a retreat
held on Dec 1, 1997, and publicized in letter to
members in February 1998, was the “training of a
broadly based, versatile general surgeon, well-trained
in all 9 primary components of surgery…” They fur-
ther acknowledged that “there must be real participa-
tion…in the decision-making process in the American
Board of Surgery” by the “various maturing fields of
surgery.” The ABS offered in its February 1998 com-
munication to its membership to create a vascular
sub-board to “advise and make recommendations to
the Vascular Examination Committee of the ABS and
to the Board of Directors of the ABS concerning all
issues related to vascular surgery.” This offer is an
attempt to both preserve what the ABS considers to
be its proper domain and give vascular surgery a
longer leash. I agree with the intent of the ABS, but
I fear that their offer is inadequate because it does
not and legally cannot give us operational control of
all issues pertaining to vascular surgery, including
those in the domain of the RRC for surgery. This
solution perpetuates our dependence on the good
will of the ABS. On April 16, 1998, Drs William
Baker and William Abbott, presidents of our 2
national societies, sent a letter to Drs Josef Fischer
and Wallie Ritchie, Jr, outlining their vision of what
this sub-board would look like. The joint council of
the national societies will consider the ABS response
in June.
If a sub-board is accepted, its effectiveness must
be challenged promptly. As conventional index cases
drop, general surgical resident experiences must be
reduced so that fellows can be trained adequately.
The RRC for surgery has the authority to take disci-
plinary action in this setting. Can the sub-board pro-
tect the vascular program in this scenario? Will the pro-
grams with sufficient index cases be allowed to train
more vascular fellows when this means a reduction in
vascular experience for the general surgery residents? I
believe that controversial issues will always be adjudi-
cated for what’s best for general surgery until vascular
surgery has its own RRC.
Certainly each party understands the conse-
quences of failing to reach an agreement. Explicit
threats are unnecessary. Consider what is really ger-
mane to the ABS. It believes that the ABS must
“evolve further into an umbrella organization
encompassing the entirety of contemporary surgery”
(ABS retreat proposal dated Dec 1, 1997) and that
“nothing would be so disastrous as to have vascular
surgery establish a primary board, which could cause
the dissembling of the American Board of Surgery to
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the detriment of both the ABS and vascular surgery”
(Joseph E. Fischer, MD, at the Oct 30, 1997, meet-
ing of leadership representatives of the ABS, the Joint
Vascular Societies, and the Association of Program
Directors in Vascular Surgery). I believe the former
true and the latter false.
What possible argument could we make that
would convince the ABS to relinquish authority? I
believe that this question is moot. It has a public rela-
tions problem. It is perceived as arrogant and out of
touch, nonreactive to changing realities. Subspecialties
are rapidly emerging and are increasingly frustrated
with the ABS. It is time for the ABS leadership to rec-
ognize that they can only maintain overall leadership 
in the entirety of contemporary surgery if they dele-
gate authority and responsibility, while maintaining
accountability. We must persuade the ABS that it can
and must change with the times, that it can do so and
maintain leadership. The compromise solution that
works for both parties is the establishment of a con-
joint board of vascular surgery, sponsored by both the
ABS and the American Board of Thoracic Surgery
(ABTS).10
A conjoint board is similar to a primary board,
because it has the authority to define the criteria for
certification in an area and, as such, request the
development of a residency review committee. The
difference between a primary and a conjoint board is
that the directors of the conjoint board are appoint-
ed by one or both of 2 sponsoring boards that for us
would mean the ABS and the ABTS. Currently, 35%
of certificate holders on the ABTS perform 50 or
more vascular cases per year.11 These directors
would come from nominations from organizations
with direct interests in vascular surgery. The policies
of the conjoint board must conform to those of the
sponsoring boards, but the day-to-day operations
would not be influenced.
Game theory teaches us that games in business
are played in a fog. Perceptions, accurate or not,
drive behavior, and the task of shaping competitors’
perceptions is an essential ingredient in business
strategy. Changing perceptions is what defines tac-
tics. The first step in negotiation is to pass the cred-
ibility test. Are we willing to acquire endovascular
skills, regardless of the cost? Are we willing to leave
our practices for significant periods for specialized
training, if that is our only recourse? Are we willing
to take legal measures if qualified surgeons are
denied access to interventional suites? Are we willing
to activate the American Board of Vascular Surgery
if the ABS does not relinquish the necessary free-
doms we need for maintaining the level of vascular
care? What we don’t do sends a message to those
with whom we are negotiating.
I am often asked, “How did you get the radiolo-
gy chair to agree to let his interventional section
merge with vascular surgery?” The answer is simple. I
didn’t get him to do anything that was not in his best
interest. These arrangements made sense. Internal
conflicts are bad for any organization, because they
inevitably channel energy towards negative ends. Take
advantage of the competition between interventional
radiologists and cardiologists, and recognize that you
bring a patient-base, as well as your technical exper-
tise. Persuade your dean or the CEO of your medical
center at an early stage of negotiations that 2 groups
with overlapping skills working together add value to
their product.
I am told that many groups have tentatively
agreed on the center concept in principle, but cannot
agree on the financial splits. This is not surprising,
because creating business is the cooperation aspect of
this process, whereas dividing the pie is the competi-
tion aspect. This is made more difficult when depart-
ment chairs realize their potential losses. In an aca-
demic institution, the dean must serve as a mediator,
using the principle of settlement escrow. Each party
confides in the mediator the minimum needs for a
deal, without disclosing this information to one
another. The mediator explores whether the posi-
tions cross and works out a compromise within the
boundaries given. If there is no common ground, the
mediator informs the parties, and they can continue
to negotiate without knowing each other’s position.
Settlement escrow allows people to negotiate in a
fog. When the parties in negotiation feel safe enough
to make reasonable demands, they are more likely to
reach an agreement. In the private practice situation,
an honest broker may be hard to find. If there is a
mutually beneficial deal to be made, however, pro-
fessional mediators can be hired.
Governance of the center will be an evolving
process. The Joint Councils of The Society Vascular
Surgery and International Society for Cardiovascular
Surgery and the Executive Council of the Society for
Cardiovascular and Interventional Radiology have
approved a statement that would allow for shared
administrative duties between vascular surgery and
interventional radiology. Our center has been in exis-
tence since July 1997 and fulfills the criteria set forth
in this document. To date, our first trainee has
achieved great proficiency in catheter-based tech-
niques, which has been supplemented by a 3-month
experience in Malmo, Sweden. It has been an eye-
opening experience for me to watch an intervention-
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al radiologist train a vascular surgeon. The product is
incredible, with skills and creativity beyond the tradi-
tional surgeon or radiologist. This is added value for
us, but the radiologist’s worst fear. We must assure
them that we are not interested in replacing them.
They are essential to the overall service of the group.
In this transition period, we will still be surgeons and
they will still be radiologists, even though we may
share some skills. Our perspectives and approaches will
differ. In time, as the vascular surgery–interventional
radiology hybrids begin to affect practice patterns, a
reassessment of manpower needs will be required as
everyone’s job description changes.
Lastly, I would like to address the issue of the
government regulation of new technology. The
FDA has the responsibility of addressing safety and
efficacy issues associated with the use of drugs and
devices. The regulation of medical devices has esca-
lated as a result of the risk-adverse American public
(personal communication, Dorothy Abel). I believe
that its leadership understands our needs and is try-
ing to strike a balance between protecting our citi-
zens and delaying implementation of improved
treatment modalities. It is axiomatic that in the eval-
uation of rapidly changing technology, the random-
ized clinical trial is outmoded. By the time the trial
is over, the technology is already obsolete. This has
become quite apparent in the aortic graft trials.
Europeans are benefiting from design improve-
ments, and we are required to use antiquated prod-
ucts lest we violate protocol. Of even more concern
is the probability that approval will be given to out-
moded technology, which, when released for gener-
al consumption, will result in significant morbidity
that might be avoided if a mechanism existed that
allowed immediate implementation of safer designs.
Efforts such as the FDA reengineering initiatives
and the new FDA Modernization Act are certainly
steps in the right direction (more information about
each can be found on the Center for Devices and
Radiological Health web site).
I propose that we solve this problem by creating
FDA-approved centers for endovascular grafts. I
propose that instead of IDE meaning investigation-
al device exemption, the “I” represent institutional.
A mechanism must be established by which proven,
reliable investigators in the United States can partic-
ipate in product evaluation and changes in technol-
ogy can be rapidly incorporated in product design.
This is a rapidly iterative process; product approval
cannot keep pace with design improvements, and
our patients will be deprived of the best possible
care. Ms Abel tells me that she is not necessarily
opposed to this suggestion, but that it will be difficult
to convince manufacturers to support such studies.
She sees no reason why “improved” devices can’t be
investigated concurrently with earlier generation
products. We must convince the manufacturers to
keep their products in the United States and provide
our expertise for the design and completion of prop-
er clinical trials that lead to quick, no-hassle approvals.
This is our state as we approach the millennium.
First, despite all our scientific discoveries and
advances in patient care, we have lost control of
much of our specialty. We have milled around for too
long. We lack fundamental skills in an increasingly
important means of therapy and, more importantly,
do not have the means to get these skills on a mass
scale. Second, a body whose stated goal, by defini-
tion, conflicts with our own regulates us. Third, we
are in danger of becoming second-class citizens in the
larger world of vascular surgery because of an anti-
quated method of evaluating new technology.
What combination of shrewdness and boldness
will help us implement what we know to be right?
Vascular surgery is at a defining moment; a time
when we must be prepared to commit to irreversible
courses of action that will shape our identity for
years to come. In the ongoing discussions between
the ABS and the interventional radiologists, we will
either live up to our ideals and emerge as a small but
independent and vibrant specialty, or pay our ideals
lip service and suffer the consequences.
The hyper rhetoric associated with the discussions
with the ABS is understandable. We both fear obliv-
ion. Unfortunately, the negotiations with the ABS did
not occur in a fog, and each side knows the other’s
minimums. Our minimum was the conjoint board,
and we got less. We have to convince them that they
will grow along with us, that there is added value
when we act as complementors rather than competi-
tors. Negotiations always involve both promises and
threats, but the latter should be left implicit. The end
point of a negotiation is an agreement that doesn’t
require each party to see things in the same way. We
must convince the ABS that allowing us the authority
to make the decisions we feel necessary is the only way
that it can achieve its goal of being the guiding
umbrella organization for surgery.
It is not enough for a few organizational leaders
to try to solve these critical issues. No one is going
to give you a document that solves your problems
with the catheter-based physicians or a deed to an
angio suite. Start your negotiating process at the
local level. Remember the concepts of added value.
You have it—don’t give it away. Let your societies
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and their leadership know how important self-rule is
to you. If we ask for less, we will get less.
We face a complicated level of uncertainty,
because a range of futures is possible. This is not
uncommon when new technology is introduced. Not
only do we face the regulatory uncertainty, but we
also have no way of determining latent demand.
How many more aneurysms will we treat if stent
grafts prove durable? What becomes the ideal size for
repair when the 30-day mortality rate is less than 1%?
The same can be said of the carotid stenosis. After all,
all 80% lesions were once 50%. Will we need more
practitioners? Will we be able to train them? There
are things we can’t know, but we can be prepared for
any contingency, and that means having the authori-
ty to deal with our own needs. At the very minimum,
we need to plan for a scenario of the not-too-distant
future in which more than half of what we presently
do will be done by endovascular practitioners.12
Make a value net for your practice. Identify
opportunities for cooperation and competition.
Establish in your own mind what your added value is
and whether it can be increased. Decide whether you
need a change in the rules and whether you have the
power to change them if necessary. Understand how
the other players perceive the game. Do their per-
ceptions need change? Do you need to negotiate in a
fog? What you don’t understand you cannot change.
Gore Vidal’s zero-sum view of the world states,
“It is not enough to succeed. Others must fail.” This
strategy will not work in this marketplace. Instead,
this is a time for us to adopt Bernard Baruch’s posi-
tive-sum view: “You don’t have to blow out the other
fellow’s light to let your own shine.” This is all about
expanding the pie. I don’t believe that any of our
current conflicts are win–lose struggles. Multiple
winners are possible. We must quickly challenge the
effectiveness of the sub-board. We can once again
become masters of our universe. There is a time for
all things. For us, it is time for co-opetition.
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